Have a feature idea you'd love to see implemented?
Let us know!
NTLA Intellia Therapeutics Inc
Price (delayed)
$13.8
Market cap
$1.41B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.44
Enterprise value
$1.39B
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron.
Highlights
The company's debt fell by 14% YoY and by 4.4% QoQ
The company's quick ratio fell by 33% YoY and by 6% QoQ
Intellia Therapeutics's revenue has decreased by 17% YoY and by 6% QoQ
Key stats
What are the main financial stats of NTLA
Market
Valuations
Earnings
Shares outstanding
101.85M
Market cap
$1.41B
Enterprise value
$1.39B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.46
Price to sales (P/S)
32.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.18
Revenue
$43.09M
EBIT
-$522.28M
EBITDA
-$512.1M
Free cash flow
-$363.06M
Per share
Balance sheet
Liquidity
EPS
-$5.44
Free cash flow per share
-$3.59
Book value per share
$9.48
Revenue per share
$0.43
TBVPS
$11.62
Total assets
$1.17B
Total liabilities
$210.74M
Debt
$101.62M
Equity
$962.62M
Working capital
$605.22M
Debt to equity
0.11
Current ratio
6.73
Quick ratio
6.31
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-1,188.6%
Gross margin
100%
Net margin
-1,212.2%
Operating margin
-1,248%
Return on assets
-42.4%
Return on equity
-52%
Return on invested capital
-48.7%
Return on capital employed
-48.9%
Return on sales
-1,212.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NTLA stock price
How has the Intellia Therapeutics stock price performed over time
Intraday
5.18%
1 week
-8.73%
1 month
-33.24%
1 year
-51.51%
YTD
-54.74%
QTD
-32.85%
Financial performance
How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$43.09M
Gross profit
$43.09M
Operating income
-$537.71M
Net income
-$522.28M
Gross margin
100%
Net margin
-1,212.2%
The company's net margin fell by 36% YoY and by 10% QoQ
Intellia Therapeutics's operating margin has decreased by 33% YoY and by 9% QoQ
Intellia Therapeutics's revenue has decreased by 17% YoY and by 6% QoQ
The gross profit has contracted by 17% YoY and by 6% from the previous quarter
Growth
What is Intellia Therapeutics's growth rate over time
Valuation
What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
1.46
P/S
32.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.18
The EPS has contracted by 2.1% YoY
The stock's P/B is 72% below its 5-year quarterly average of 5.2 and 39% below its last 4 quarters average of 2.4
Intellia Therapeutics's equity has decreased by 7% YoY
The price to sales (P/S) is 66% lower than the 5-year quarterly average of 94.1 and 41% lower than the last 4 quarters average of 55.0
Intellia Therapeutics's revenue has decreased by 17% YoY and by 6% QoQ
Efficiency
How efficient is Intellia Therapeutics business performance
The ROS has contracted by 36% YoY and by 10% from the previous quarter
Intellia Therapeutics's ROE has decreased by 28% YoY and by 4.6% from the previous quarter
The ROA has contracted by 26% YoY and by 4.2% from the previous quarter
Intellia Therapeutics's ROIC has decreased by 17% YoY and by 3.8% from the previous quarter
Dividends
What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NTLA.
Financial health
How did Intellia Therapeutics financials performed over time
The company's quick ratio fell by 33% YoY and by 6% QoQ
NTLA's current ratio is down by 31% year-on-year and by 7% since the previous quarter
The company's debt is 89% lower than its equity
The company's debt fell by 14% YoY and by 4.4% QoQ
Intellia Therapeutics's equity has decreased by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.